Neuro3d Initiates Phase I Trials with ND7001, a New Mechanism Antidepressant and Anxiolytic Compound
Neuro3d announced the initiation of Phase I clinical trials with ND7001, a new type of antidepressant drug with anxiolytic activity. ND7001 acts on a new target that has never been associated with depression or anxiety. It is the first representative of a new generation of psycho-active compounds potentially devoid of several problems seen with existing treatments.
Initially, a double-blind, placebo-controlled, single, dose-escalation study will be conducted to investigate safety, tolerability and pharmacokinetics. Thereafter, a multiple-dose study will be conducted which will also include qEEG recordings to provide evidence of CNS effects and active dose range.
"ND7001 is the first drug of its kind to enter clinical development," noted Cesare Mondadori, CSO of Neuro3d. "The drug acts via a new mechanism and is well tolerated in preclinical studies. Our studies in animals show that ND7001 not only meets the criteria of an antidepressant but also of an anxiolytic compound."
Most read news
Other news from the department research and development

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.